News & Updates

The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.

A phase II trial demonstrated significantly longer progression-free survival (PFS) and overall survival (OS) in Chinese patients with advanced pancreatic cancer (APC) who received first-line treatment with nab-paclitaxel plus S-1 (AS) vs nab-paclitaxel plus gemcitabine (AG).

A secondary post hoc analysis of the phase III SPARTAN trial shows that patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who received prior prostate-directed local therapy (LT) had longer metastasis-free survival (MFS) when treated with apalutamide vs those without prior LT.

A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.

DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.

High expression of Wilms’ tumor 1-associating protein (WTAP) in patients with nonsmall cell lung cancer (NSCLC) appears to promote poor clinical outcomes, suggests a study.